Balyasny Asset Management
OREX

Balyasny Asset Management’s Orexigen Therapeutics, Inc. OREX Stock Holding History

Balyasny Asset Management’s Portfolio OREX Stock Details OREX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-7,835
Closed -$165K – 1662
2015
Q3 		$165K Buy
+7,835
New +$268K ﹤0.01% 1026

Other funds holding OREX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
FCMI
Foresite Capital Management II Larkspur, California $29.2M AUM 44.84% 1-Year Est. Return
SC
Samlyn Capital New York $5.86B AUM 36.3% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Balyasny Asset Management's OREX Position: Q4 2015 in Review

Balyasny Asset Management sold out of Orexigen Therapeutics, Inc. (OREX) in Q4 2015, closing a stake of 7,835 shares — an estimated $165K sold.

Balyasny Asset Management first reported a position in OREX in Q3 2015 and held it in 1 quarter. The position peaked at $165K in Q3 2015. 121 funds tracked by Wall St. Rank hold OREX as of Q4 2015.

  • Balyasny Asset Management reported no remaining Orexigen Therapeutics, Inc. position as of Q4 2015 after selling out during the quarter.
  • Balyasny Asset Management sold 7,835 Orexigen Therapeutics, Inc. shares in Q4 2015, an estimated $165K.
  • Balyasny Asset Management first reported a position in Orexigen Therapeutics, Inc. in Q3 2015 and held it in 1 quarter.
  • Balyasny Asset Management's Orexigen Therapeutics, Inc. position peaked at $165K in Q3 2015.
  • 121 funds tracked by Wall St. Rank held Orexigen Therapeutics, Inc. as of Q4 2015.

Based on Balyasny Asset Management's 13F filing for Q4 2015, filed 16 Feb 2016.